GPT and metabolic dysfunction-associated steatotic liver disease: STZ/HFD NAFLD mice receiving ALT-100 mAb treatment demonstrated significant disappearance of hepatocyte lipid accumulation and intrahepatic fat vacuole steatosis and near absence of hepatocyte ballooning and lobular inflammation (Figure 3C, fourth panel).